SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed
Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/26/2017 11:10:18 AM - Followers: 4 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US

 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
 
 
 
 
 
OXBDF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#444   A GREAT read, and a 14p recommendation:- marcusl2 06/26/17 11:10:18 AM
#443   FT article marcusl2 06/23/17 04:53:38 PM
#442   https://seekingalpha.com/news/3275240-novartis-car-t-candidate-ctl019-shows-sust marcusl2 06/23/17 11:10:34 AM
#441   Prof. Gill / The results of using the marcusl2 06/22/17 06:30:57 AM
#440   Tom Whitehead, father of emily (patient #1) to marcusl2 06/21/17 05:07:49 AM
#439   https://www.youtube.com/watch?v=Mxzv0pS1uUw I can see why Novartis were so ex marcusl2 06/19/17 10:02:11 AM
#438   Oxford Biomedica PLC Findings from Phase II JULIET Study marcusl2 06/14/17 01:28:16 PM
#437   "We are pleased the interim results from JULIET marcusl2 06/07/17 03:48:31 PM
#436   London, UK - 7 June 2017: Oxford BioMedica marcusl2 06/07/17 06:23:04 AM
#435   Dr. Carl June, a University of Pennsylvania researcher georgejjl 06/06/17 06:49:08 AM
#434   HTTP://meetinglibrary.asco.org/record/147114/abstract HTTP://meetinglibrary.asc marcusl2 06/04/17 05:13:58 PM
#433   Great news if we keep on getting this marcusl2 05/31/17 04:23:14 AM
#432   CD19 CAR-T cells combined with ibrutinib to induce georgejjl 05/27/17 07:52:13 AM
#431   Job Description marcusl2 05/26/17 03:36:09 AM
#430   Enhancing titres of therapeutic viral vectors using the georgejjl 05/24/17 08:58:09 PM
#429   Global Manufacturing of CAR T Cell Therapy at georgejjl 05/24/17 08:56:00 PM
#428   5T4 oncofoetal antigen: an attractive target for immune georgejjl 05/24/17 08:52:07 PM
#427   First-in-human trial of an anti-5T4 antibody-monomethylauristatin conj georgejjl 05/24/17 08:47:53 PM
#426   Pfizer and Oxford BioMedica's 5T4 ADC georgejjl 05/24/17 08:41:57 PM
#425   5T4 ADC at Medimmune georgejjl 05/24/17 08:36:15 PM
#424   Oxford Biomedica and Novartis CAT T cell therapy georgejjl 05/16/17 10:20:24 PM
#423   CTL-019 BLAs awarded for: paediatric r/r B-ALL and marcusl2 05/01/17 11:32:44 AM
#422   Another Win for CAR-T Therapy marcusl2 04/29/17 10:36:48 AM
#421   Highlights from marcusl2 04/27/17 05:55:53 PM
#420   http://www.oxfordbiomedica.co.uk/uploads/corporate-presentation/interims2016-ana marcusl2 04/27/17 05:55:23 PM
#419   Novartis said it will continue to aggressively strengthen marcusl2 04/25/17 03:11:25 PM
#418   Finally! Novartis AG (NVS) to Release Long-Awaited Juliet marcusl2 04/25/17 10:41:47 AM
#417   Watch this!!! georgejjl 04/19/17 07:09:01 PM
#416   HTTPS://www.youtube.com/watch?v=ZxPssFDfmgQ marcusl2 04/19/17 04:47:35 PM
#415   Bingo, great news marcusl2 04/18/17 05:35:39 AM
#414   https://www.youtube.com/watch?v=4MxH3X9diSc&feature=youtu.be marcusl2 04/13/17 05:06:25 PM
#413   https://www.youtube.com/watch?v=_oOWzA4bz-s marcusl2 04/11/17 03:46:42 AM
#412   Novartis is clearly looking like it will be marcusl2 04/08/17 04:59:27 AM
#411   Novartis says U.S. regulator grants speedy review of georgejjl 03/30/17 02:14:49 AM
#410   Novartis announces first CAR-T cell therapy BLA for marcusl2 03/29/17 04:50:13 PM
#409   Oxford Biomedica PLC Publication in the Journal Nature Communications marcusl2 03/27/17 06:05:01 AM
#408   OXB-302 (CAR-T 5T4) marcusl2 03/18/17 06:12:47 AM
#407   2 great ‘hidden’ shares for growth investors marcusl2 03/17/17 09:50:09 AM
#406   Earnings Call Transcript georgejjl 03/17/17 08:04:28 AM
#405   A MUST SEE georgejjl 03/16/17 07:03:34 AM
#404   Plenty of buying. Maybe news is close? marcusl2 03/03/17 05:55:55 AM
#403   Oxford Biomedica lauds “encouraging” trial results from a georgejjl 02/24/17 04:29:29 AM
#402   Conclusions: Both CPM and TroVax induced highly beneficial marcusl2 02/23/17 03:33:31 PM
#401   HTTP://abstracts.asco.org/194/AbstView_194_178575.html MVA-5T4 immunotherapy marcusl2 02/23/17 08:55:29 AM
#400   Very interesting georgejjl 02/15/17 10:57:49 PM
#399   Oxford Biomedica Set To Flirt With Venture Financing georgejjl 02/13/17 08:03:13 PM
#398   Such high ambitions draw an obvious comparison between marcusl2 02/13/17 05:01:50 PM
#397   3 weeks marcusl2 01/31/17 09:18:42 AM
#396   How do you understand that patent George as marcusl2 01/29/17 03:32:37 PM
#395   5T4 and Cellectis patent georgejjl 01/29/17 10:49:06 AM
PostSubject